Necrotizing Enterocolitis
Conditions
Brief summary
The aim of this study is to evaluate the effectiveness of pentoxifylline versus probiotics supplementation as adjuvant therapy for preterm neonates with necrotizing enterocolitis.
Detailed description
This randomized clinical trial includes 75 preterm infants who met the inclusion criteria for stage I and stage II NEC. Patients are allocated randomly into three groups (each included 25 neonates); group I (traditional therapy group) received antibiotics according to culture and sensitivity results, group II (pentoxifylline group) received antibiotics and IV pentoxifylline at a dose of 30 mg/ Kg given over 6 hours daily until discharge from the unit, and group III (probiotics group) received antibiotics and probiotics sachets supplementation in a dose of 100 mg mixed with 10 ml sterile water and given by Ryle tube once daily until discharge. The serum level of high-mobility group box protein 1 (HMGB-1), intestinal fatty acid binding proteins (I-FABP), and total antioxidant capacity (TAC) were measured on admission and at discharge.
Interventions
DRUGPentoxifylline
Pentoxifylline 30 mg/kg given over 6 hours daily
probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 37 Weeks
Healthy volunteers
No
Inclusion criteria
* Male and female preterm neonates less than 37 weeks gestational age * Suffering from necrotizing enterocolitis (NEC), according to Modified Bell's system which was first proposed by Bell et al., 1978 as stage I (suspected), II (proven) . * Diagnosis of NEC depends on; history, physical examination, laboratory and radiographic findings . * Signs and symptoms of NEC (at least three or more ), including; unstable temperature, apnea, increased residual milk in stomach, mid abdominal distension, vomiting coffee-like substances, bloody stool * Laboratory findings including; thrombocytopenia, hypernatremia, metabolic acidosis, neutropenia and leukocytosis. * Anterior posterior abdominal radiograph is used for diagnosis in which pneomatosis intestinalis in stage II NEC
Exclusion criteria
* Term and post term neonates * Neonates with congenital infections * Neonates with major congenital anomalies * Neonates with stage III NEC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rate | 2 months | record mortality rate in each group during treatment |
| complications and side effects | 2 months | record any complications or side effects of the treating drugs |
| Inflammatory parameter | 2 months | Change in serum C-reactive protein at baseline and after 2 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in serum high-mobility group box protein 1 (HMGB1) | 2 months | blood sample will be collected at baseline and after 2 months |
| change in serum Intestinal fatty acid binding protein (I-FABP). | 2 months | blood sample will be collected at baseline and after 2 months |
| change in serum total antioxidant capacity (TAC) | 2 months | Blood sample will be collected at baseline and after 2 months |
Countries
Egypt
Outcome results
None listed